Dr. Elliot Stieglitz is a physician-scientist at the University of California, San Francisco whose research focuses on children diagnosed with juvenile myelomonocytic leukemia (JMML). He recently chaired a study, ADVL1512, a phase II clinical trial that tested the safety of trametinib in children with relapsed JMML. This trial met its primary objective and closed to accrual at the end of 2022. Dr. Stieglitz’s main laboratory focus is on developing novel therapies for JMML including CAR-T cells. He has generated patient-derived xenograft (PDX) models of JMML that will serve as the pre-clinical model in which to test CAR-T cells on this grant. These PDXs were generated in collaboration with Dr. Eric Padron, a key opinion leader in CMML and a collaborator on this grant. Dr. Stieglitz has also collaborated extensively with Dr. Tasian, an international leader in CAR-T therapy who is a Co-PI on this grant. This multi-disciplinary team will work together to advance CLL-1 CAR-T cells and trametinib into the clinic for CMML and JMML patients.